Examining Caffeine as a Treatment for Antidepressant-induced Arousal Dysfunction in Women
Female Sexual Arousal Disorder
About this trial
This is an interventional treatment trial for Female Sexual Arousal Disorder focused on measuring female sexual dysfunction, female sexual arousal disorder, caffeine
Eligibility Criteria
Inclusion Criteria: Between the of ages 18-55 Fluent in English Experience antidepressant-induced arousal difficulties Experience regular menstrual periods (i.e., not perimenopausal or menopausal) Exclusion Criteria: A history or current diagnosis of panic attacks or panic disorder A history or current diagnosis of sexually transmitted disease(s) A history of major pelvic surgery that caused nerve damage Currently taking beta blockers, antipsychotics, anti-anxiolytics, hormonal contraceptives (unless the participant has been taking it for over 3 months), or any other medical treatment to enhance sexual response Other medical conditions or procedures that would preclude the participant's participation in the study (e.g., urinary tract infection, neurological impairment due to diabetes or stroke, or spinal cord damage) A history of childhood sexual abuse (CSA) that occurred prior to age 16
Sites / Locations
- The University of Texas at Austin, Sexual Psychophysiology Laboratory
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Caffeine
Placebo
During one of two counterbalanced experimental sessions, participants will ingest 300mg of caffeine orally via capsules.
During one of two counterbalanced experimental sessions, participants will ingest placebo orally via capsules.